163706-36-3

163706-36-3 structure

Name: Cangrelor tetrasodium
Chemical Name: tetrasodium,[dichloro(phosphonato)methyl]-[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-oxidophosphoryl]oxyphosphinate
CAS Number: 163706-36-3
Molecular Formula: C₁₇H₂₁Cl₂F₃N₅Na₄O₁₂P₃S₂
Molecular Weight: 864.286
Catalog: Signaling Pathways GPCR/G Protein P2Y Receptor
Create Date: 2018-02-28 08:00:00
Modify Date: 2024-01-11 20:06:53
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist[1][2].

Name	tetrasodium,[dichloro(phosphonato)methyl]-[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-oxidophosphoryl]oxyphosphinate
Synonyms	Tetrasodium 5'-O-[({[dichloro(phosphonato)methyl]phosphinato}oxy)phosphinato]-N-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine Cangrelor tetrasodium Adenosine, 5'-O-[[[(dichlorophosphonomethyl)hydroxyphosphinyl]oxy]hydroxyphosphinyl]-N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-, sodium salt (1:4) UNII-2144G00Y7W Cangrelor tetrasodium (USAN)

Description	Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> P2Y Receptor Research Areas >> Inflammation/Immunology
In Vitro	Cangrelor tetrasodium is the only potent intravenous direct and specific adenosine diphosphate (ADP) P2Y12 receptor antagonist[1]. Cangrelor tetrasodium has pKb of 8.6-9.2 for hP2Y12 receptor[3].
In Vivo	Cangrelor tetrasodium (10 mg/kg) not only significantly decreases BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreases the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice[2].
References	[1]. Bhattad VB, , et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019;7(17):408. [2]. Zhan T, Wei T, et al. Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice. Mol Immunol. 2020;120:83-92. [3]. Bekő K, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain. J Thromb Haemost. 2017;15(6):1223-1235.